97/348/EC: Commission Decision of 23 May 1997 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (Text with EEA relevance)

Decision · 6 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

1. The Community shall purchase the following strains of foot-and-mouth disease antigen: - A22 Iraq: 2 000 000 doses - C1: 5 000 000 doses - ASIA 1: 5 000 000 doses up to a maximum cost of ECU 2,4 million. 2. The antigen mentioned in paragraph 1 shall be supplied by Rhône Mérieux. 3. The Community shall make arrangements for formulation, production, bottling and distribution of vaccines against foot-and-mouth disease produced from antigens mentioned in paragraph 2 initially up to a maximum cost of ECU 1,5 million. 4. The action referred to in paragraph 3 shall be organized by the Commission.

Article 2

1. The Community shall make arrangements for formulation, production, bottling and distribution of vaccines against foot-and-mouth disease produced from antigens kept in existing antigen banks, initially up to a maximum cost of ECU 1,5 million. 2. The action referred to in paragraph 1 shall be organized by the Commission.

Article 3

The measures mentioned in Article 1 (3) and Article 2 (1) shall be carried out by the Commission in cooperation with Rhône Mérieux.

Article 4

1. To meet the objectives of Articles 1, 2 and 3 the Commission shall conclude contracts, in the name of the European Community, with Rhône Mérieux. 2. The Director-General of the Directorate-General for Agriculture shall be authorized to sign the contracts on behalf of the European Commission. 3. Payment to Rhône Mérieux shall be made in accordance with the terms of the contracts provided for in paragraph 1.

Article 5

The antigen referred to in Article 1 (1) shall be divided between the existing antigen banks as follows: (a) Lyon: 2 000 000 doses of A22 Iraq, (b) Brescia: 2,5 million doses of C1 and of ASIA 1, (c) Pirbright: 2,5 million doses of C1 and of ASIA 1.

Article 6

This Decision is addressed to the Member States. Done at Brussels, 23 May 1997. For the Commission Franz FISCHLER Member of the Commission (1) OJ No L 224, 18. 8. 1990, p. 19. (2) OJ No L 168, 2. 7. 1994, p. 31. (3) OJ No L 368, 31. 12. 1991, p. 21. (4) OJ No L 280, 13. 11. 1993, p. 33. (5) OJ No L 269, 11. 11. 1995, p. 29. (6) OJ No C 346, 16. 11. 1996, p. 27.

Other acts of the same type

Council Decision (CFSP) 2023/161 of 23 January 2023 amending Decision (CFSP) 2021/649 on Union support for activities of the ATT Secretariat in support of the implementation of the Arms Trade Treaty Council Decision (CFSP) 2023/162 of 23 January 2023 on a European Union mission in Armenia (EUMA)Council Decision (EU) 2023/187 of 23 January 2023 on the position to be adopted on behalf of the European Union within the Sanitary and Phytosanitary Sub-Committee established by the Association Agreement between the European Union and the European Atomic Energy Community and their Member States, of the one part, and Georgia, of the other part, as regards the modification of Annex XI-B to that Agreement Council Decision (EU) 2023/658 of 23 January 2023 on the signing, on behalf of the European Union, and provisional application of the Agreement between the European Union and the Republic of Seychelles on access for Seychelles fishing vessels to the waters of Mayotte Decision (EU) 2023/367 of the European Parliament of 19 January 2023 extending the term of office of the Committee of Inquiry to investigate the use of the Pegasus and equivalent surveillance spyware Decision (EU) 2023/136 of the European Parliament and of the Council of 18 January 2023 amending Directive 2003/87/EC as regards the notification of offsetting in respect of a global market-based measure for aircraft operators based in the Union (Text with EEA relevance)Commission Implementing Decision (EU) 2023/264 of 18 January 2023 on the applicability of Article 34 of Directive 2014/25/EU of the European Parliament and of the Council to the award of contracts for the activity related to mail service management services in Italy (notified under document C(2023) 331) (Only the Italian text is authentic) (Text with EEA relevance)Council Decision (CFSP) 2023/122 of 17 January 2023 amending Joint Action 2008/124/CFSP on the European Union Rule of Law Mission in Kosovo (This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.), EULEX KOSOVO Council Decision (CFSP) 2023/123 of 17 January 2023 amending Decision (CFSP) 2019/97 in support of the Biological and Toxin Weapons Convention in the framework of the EU Strategy against Proliferation of Weapons of Mass Destruction Council Decision (CFSP) 2023/124 of 17 January 2023 in support of the Hague Code of Conduct and ballistic missile non-proliferation in the framework of the implementation of the EU Strategy against Proliferation of Weapons of Mass Destruction Council Decision (EU) 2023/133 of 17 January 2023 appointing the members of the selection panel provided for in Article 14(3) of Regulation (EU) 2017/1939 Council Implementing Decision (EU) 2023/134 of 17 January 2023 amending Implementing Decision (EU) 2018/1696 as regards the use of videoconferencing for the hearing of candidates

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview